|
|
||||||||
Neurological Institute, Columbia-Presbyterian Medical Center, New York, NY.
Address correspondence and reprint requests to Dr. Burke, Neurological Institute, Dept of Neurology, 710 W. 168 Street, New York, NY 10032.
Prior reports of neuroleptic malignant syndrome (NMS) concerned patients with psychiatric disorders, usually schizophrenia, who were taking dopamine receptor blocking agents. We report the syndrome in a patient with Huntington disease who was treated with dopamine-depleting agents. He had a negative evaluation for malignant hyperthermia (MH), and we suggest that NMS differs from MH. The occurrence of NMS caused by dopamine-depleting agents suggests that anticholinergic properties of phenotiazines are not the only cause. Central dopaminergic systems probably participate in thermo-regulation, and dopamine depletion probably plays a pathogenetic role in this syndrome.
This article has been cited by other articles:
![]() |
R. Ankenman and M. F. Salvatore Low Dose Alpha-Methyl-Para-Tyrosine (AMPT) in the Treatment of Dystonia and Dyskinesia J Neuropsychiatry Clin Neurosci, February 1, 2007; 19(1): 65 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Adnet, P. Lestavel, and R. Krivosic-Horber Neuroleptic malignant syndrome Br. J. Anaesth., July 1, 2000; 85(1): 129 - 135. [Full Text] [PDF] |
||||
![]() |
P M Haddad Neuroleptic malignant syndrome: May be caused by other drugs.. BMJ, January 15, 1994; 308(6922): 200 - 200. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |